NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Voyageur Pharmaceuticals' Acquisition of Iodine Extraction Technology and Appointment of Dr. Brian Mueller
TL;DR
Voyageur Pharmaceuticals acquires exclusive rights to the Mueller Process, positioning itself for cost leadership in the $2.65 billion North American iodine contrast market.
The Mueller Process extracts over 90% yield from brine, converting it to 99.5% pure iodine through a closed-loop system with no hazardous emissions.
This technology enables domestic production of medical contrast agents, reducing supply chain risks and providing cleaner industrial brine for sustainable resource management.
A scientist with 40 patents developed a process that extracts medical-grade iodine from brine water while creating useful byproducts for other industries.
Found this article helpful?
Share it with your network and spread the knowledge!
Voyageur Pharmaceuticals has acquired 100% ownership of Dr. Brian Mueller's proprietary iodine extraction technology (the 'Mueller Process') and appointed Dr. Mueller as the Company's Director of Chemistry, effective immediately.
This acquisition grants Voyageur exclusive control over intellectual property supporting its iodine strategy, which is expected to enhance cost efficiency, operational flexibility, and long-term supply-chain security for its iodine extraction projects.
The Mueller Process achieves greater than 90% yield from incoming brine to technical grade iodine (greater than 85% pure) with conversion to 99.5% pure iodine. It's environmentally friendly with a closed process that produces no volatile organic compounds or hazardous emissions, and the output brine is a 'clean brine' useful for industrial applications.
Dr. Brian Mueller, PhD, is the developer of the proprietary iodine-extraction technology acquired by Voyageur and has been appointed as the Company's Director of Chemistry, effective immediately.
Voyageur made a lump sum initial cash payment and will pay Dr. Mueller a running royalty on net sales of iodine products as consideration for the acquisition, which is described as an arm's length transaction.
The Mueller Process has been tested using brine water from the Anadarko and West Texas Basins, with initial bench scale testing conducted by Dr. Mueller.
Provisional patent applications for the intellectual property were filed in 2025, and Voyageur is on track to submit full utility patent applications in 2026.
Voyageur's Streamlined API process, created by COO Bradley Willis, aims to simplify iodine contrast drug production by extracting directly from brine water in a closed loop manufacturing process. The Mueller Process may enable Voyageur to bypass the iodine flake process entirely and directly create iodine drugs through this Streamlined API process.
Voyageur expects this technology will allow them to produce high-quality, cost-effective iodine contrast agents with one of the lowest cost structures in the industry, potentially become the first U.S. company to produce iodine drugs domestically, and open the door to elemental mineral extraction from their ULI claim block in Utah.
The elemental minerals of interest for potential extraction from Voyageur's ULI claim block in the Paradox Basin, Utah are lithium, iodine, bromine, boron, magnesium, potassium, and sodium.
Curated from NewMediaWire
